中芯國際(688981.SH)第二季銷售收入環比增長3.3%、同比增長41.6%
格隆匯8月11日丨中芯國際(688981.SH)披露截至2022年6月30日止三個月的未經審核業績,第二季的銷售收入為19.03億美元,相較於2022年第一季的18.42億美元增長3.3%,相較於2021年第二季的13.44億美元增長41.6%。
2022年第二季毛利為7.5億美元,相比2022年第一季為7.5億美元,相較於2021年第二季的4.05億美元增長85.3%。
2022年第二季毛利率為39.4%,相比2022年第一季為40.7%,2021年第二季為30.1%。
2022年第二季公司擁有人應占利潤5.14億美元,環比增長15.0%,同比下降25.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.